These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

836 related articles for article (PubMed ID: 19210162)

  • 1. Low-abundance drug-resistant viral variants in chronically HIV-infected, antiretroviral treatment-naive patients significantly impact treatment outcomes.
    Simen BB; Simons JF; Hullsiek KH; Novak RM; Macarthur RD; Baxter JD; Huang C; Lubeski C; Turenchalk GS; Braverman MS; Desany B; Rothberg JM; Egholm M; Kozal MJ;
    J Infect Dis; 2009 Mar; 199(5):693-701. PubMed ID: 19210162
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevalence of antiretroviral drug resistance mutations in chronically HIV-infected, treatment-naive patients: implications for routine resistance screening before initiation of antiretroviral therapy.
    Novak RM; Chen L; MacArthur RD; Baxter JD; Huppler Hullsiek K; Peng G; Xiang Y; Henely C; Schmetter B; Uy J; van den Berg-Wolf M; Kozal M;
    Clin Infect Dis; 2005 Feb; 40(3):468-74. PubMed ID: 15668873
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of drug resistance genotypes on CD4+ counts and plasma viremia in heavily antiretroviral-experienced HIV-infected patients.
    Rodes B; García F; Gutierrez C; Martinez-Picado J; Aguilera A; Saumoy M; Vallejo A; Domingo P; Dalmau D; Ribas MA; Blanco JL; Pedreira J; Perez-Elias MJ; Leal M; de Mendoza C; Soriano V;
    J Med Virol; 2005 Sep; 77(1):23-8. PubMed ID: 16032728
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Epidemiology of primary drug resistance in chronically HIV-infected patients in Nordrhein-Westfalen, Germany, 2001-2005].
    Oette M; Kaiser R; Däumer M; Fätkenheuer G; Rockstroh JK; Knechten H; Mitrenga D; Beerenwinkel N; Sagir A; Pfister H; Häussinger D
    Dtsch Med Wochenschr; 2007 May; 132(18):977-82. PubMed ID: 17457780
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence of low-level HIV-1 variants with reverse transcriptase mutation K65R and the effect of antiretroviral drug exposure on variant levels.
    Kozal MJ; Chiarella J; St John EP; Moreno EA; Simen BB; Arnold TE; Lataillade M
    Antivir Ther; 2011; 16(6):925-9. PubMed ID: 21900725
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modest decreases in NNRTI susceptibility do not influence virological outcome in patients receiving initial NNRTI-containing triple therapy.
    Harrigan PR; Hertogs K; Verbiest W; Larder B; Yip B; Brumme ZL; Alexander C; Tilley J; O'Shaughnessy MV; Montaner JS
    Antivir Ther; 2003 Oct; 8(5):395-402. PubMed ID: 14640386
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genotypic resistance and HIV-1 subtype in Brazilian children on dual and triple combination therapy.
    Machado ES; Lambert JS; Watson DC; Afonso AO; da Cunha SM; Nogueira SA; Caride E; Oliveira RH; Sill AM; DeVico A; Tanuri A
    J Clin Virol; 2004 May; 30(1):24-31. PubMed ID: 15072750
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug resistant mutations detected by genotypic drug resistance testing in patients failing therapy in clade C HIV-1 infected individuals from India.
    Kandathil AJ; Kannangai R; Verghese VP; Pulimood SA; Rupali P; Sridharan G; Grant P; Pillay D; Abraham OC
    Indian J Med Microbiol; 2009; 27(3):231-6. PubMed ID: 19584504
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Minority variants associated with resistance to HIV-1 nonnucleoside reverse transcriptase inhibitors during primary infection.
    Nicot F; Saliou A; Raymond S; Sauné K; Dubois M; Massip P; Marchou B; Delobel P; Izopet J
    J Clin Virol; 2012 Oct; 55(2):107-13. PubMed ID: 22818969
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Primary drug-resistance in HIV-positive patients on initiation of first-line antiretroviral therapy in Germany.
    Oette M; Kaiser R; Däumer M; Akbari D; Fätkenheuer G; Rockstroh JK; Stechel J; Rieke A; Mauss S; Schmalöer D; Göbels K; Vogt C; Wettstein M; Häussinger D
    Eur J Med Res; 2004 May; 9(5):273-8. PubMed ID: 15257882
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selection of drug-resistant HIV-1 during the early phase of viral decay is uncommon in treatment-naïve patients initiated on a three- or four-drug antiretroviral regimen including lamivudine.
    Bergroth T; Ekici H; Gisslén M; Loes SK; Goh LE; Freedman A; Lampe F; Johnson MA; Sönnerborg A
    J Med Virol; 2009 Jan; 81(1):1-8. PubMed ID: 19031460
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence of minor variants of HIV strains at reverse transcriptase position 103 in therapy-naïve patients and their impact on the virological failure.
    Balduin M; Oette M; Däumer MP; Hoffmann D; Pfister HJ; Kaiser R
    J Clin Virol; 2009 May; 45(1):34-8. PubMed ID: 19375978
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transmission of HIV-1 minority-resistant variants and response to first-line antiretroviral therapy.
    Peuchant O; Thiébaut R; Capdepont S; Lavignolle-Aurillac V; Neau D; Morlat P; Dabis F; Fleury H; Masquelier B;
    AIDS; 2008 Jul; 22(12):1417-23. PubMed ID: 18614864
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficient suppression of minority drug-resistant HIV type 1 (HIV-1) variants present at primary HIV-1 infection by ritonavir-boosted protease inhibitor-containing antiretroviral therapy.
    Metzner KJ; Rauch P; von Wyl V; Leemann C; Grube C; Kuster H; Böni J; Weber R; Günthard HF
    J Infect Dis; 2010 Apr; 201(7):1063-71. PubMed ID: 20196655
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug resistance among chronic HIV-1-infected patients naïve for use of anti-retroviral therapy in Sao Paulo city.
    Gonsalez CR; Alcalde R; Nishiya A; Barreto CC; Silva FE; de Almeida A; Mendonça M; Ferreira F; Fernandes SS; Casseb J; Duarte AJ
    Virus Res; 2007 Nov; 129(2):87-90. PubMed ID: 17686543
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term immunologic and virologic responses in patients with highly resistant HIV infection who are treated with an incompletely suppressive antiretroviral regimen.
    Gandhi T; Nagappan V; Cinti S; Wei W; Kazanjian P
    Clin Infect Dis; 2007 Oct; 45(8):1085-92. PubMed ID: 17879930
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Response to antiretroviral therapy in HIV-infected patients attending a public, urban clinic in Kampala, Uganda.
    Spacek LA; Shihab HM; Kamya MR; Mwesigire D; Ronald A; Mayanja H; Moore RD; Bates M; Quinn TC
    Clin Infect Dis; 2006 Jan; 42(2):252-9. PubMed ID: 16355337
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HIV-1-resistant strains during 8-week on 8-week off intermittent therapy and their effect on CD4+ T-cell counts and antiviral response.
    Izopet J; Marchou B; Charreau I; Sauné K; Tangre P; Molina JM; Aboulker JP;
    Antivir Ther; 2008; 13(4):537-45. PubMed ID: 18672532
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiretroviral resistance among HIV-infected persons who have died in British Columbia, in the era of modern antiretroviral therapy.
    Recsky MA; Brumme ZL; Chan KJ; Wynhoven B; Yip B; Dong WW; Heath KV; Montaner JS; Levy AR; Hogg RS; Harrigan PR
    J Infect Dis; 2004 Jul; 190(2):285-92. PubMed ID: 15216463
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Compilation and prevalence of mutations associated with resistance to non-nucleoside reverse transcriptase inhibitors.
    Tambuyzer L; Azijn H; Rimsky LT; Vingerhoets J; Lecocq P; Kraus G; Picchio G; de Béthune MP
    Antivir Ther; 2009; 14(1):103-9. PubMed ID: 19320243
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 42.